FOLH1 and prostate carcinoma: Lutetium 177 [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) is aprostate-specific membrane antigen (PSMA)–targeted radioligand therapy formetastatic castration-resistant prostate cancer (mCRPC).